© 2026 Monument Traders Alliance, LLC
We had a lot of fun with this stock during its last big run.
It was an earnings winner, and we traded it over and over on the way up. Then it got crushed.
There was a lawsuit; I think one of their competitors got FDA approval for something, and the whole thing turned into a mess.
Now all of that is behind them. The stock jumped on its latest earnings report, and it’s a fresh earnings winner again.
I get the same question from you guys all the time: “Nate, if we only want to buy in the buy zone, why are you buying one that’s out of the buy zone?”
My answer is that earnings winners are different. They gap, and they can keep going.
This one has something extra going for it, too. My two favorite sandboxes to play in are earnings winners and stocks with a high short float, and this name is in both.
A high short float means a big chunk of the shares are sold short by traders betting the stock falls, and when it keeps climbing, they have to buy back in.
We’re playing it as a second-day play, buying the day after the earnings pop, and it’s moving higher. We’re in it, and I’ll probably add more.
On the chart, there’s one level where more shares changed hands than anywhere else during the last run. I think the stock heads back there, and I’m buying extra time with the options to give it room to get there.
In the video, I show you the name, that level, and the exact calls I’d buy to let it run.
